GLPwatch

Weight Loss Therapies and Hypertension Benefits.

Biomedicines · 2024

Last updated 2026-05-28

This review looks at how different weight loss treatments, including GLP-1 drugs like liraglutide and semaglutide, affect blood pressure. It explains that these treatments may help by targeting shared causes of obesity and high blood pressure, such as insulin resistance and overactive hormone systems.

AI summary of the abstract below.

JournalBiomedicines, 2024
Citations8
Relative citation ratio1.44
NIH percentile63
Molecules
Conditions studied Obesity, Cardiovascular Risk Reduction

Abstract

Obesity and hypertension have become an international health issue, with detrimental consequences on patients. Obesity and hypertension share common pathophysiological mechanisms, such as overactivity of the renin-angiotensin-aldosterone and the sympathetic nervous systems, insulin resistance, and disruption of the leptin pathway. Approved therapies for obesity and overweight include phentermine/topiramate, orlistat, naltrexone/bupropion, the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide, tirzepatide, and bariatric surgery. This review gives the clinical data in a thorough manner and explains in detail how each of the previously mentioned therapies affects blood pressure levels.

Verbatim abstract via PubMed 39457606 ↗